Structural Dynamics Behind Clinical Mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis Associated With Pyrazinamide Resistance
Pyrazinamide (PZA) is one of the main FDA approved drugs to be used as the first line of defense against Mycobacterium Tuberculosis (MTB). It is activated into pyrazinoic acid (POA) via MTB's pncA gene-encoded pyrazinamidase (PZase). Mutations are most commonly responsible for PZA-resistance in...
Main Authors: | Aamir Mehmood, Muhammad Tahir Khan, Aman Chandra Kaushik, Anwar Sheed Khan, Muhammad Irfan, Dong-Qing Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-12-01
|
Series: | Frontiers in Bioengineering and Biotechnology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fbioe.2019.00404/full |
Similar Items
-
Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis
by: Shi D, et al.
Published: (2022-08-01) -
Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients
by: Rong Li, et al.
Published: (2023-06-01) -
Use of genetic mutations for prediction of resistance to pyrazinamide in M. tuberculosis strains
by: Daniela M Cirillo, et al.
Published: (2015-01-01) -
Marine Natural Products and Drug Resistance in Latent Tuberculosis
by: Muhammad Tahir Khan, et al.
Published: (2019-09-01) -
A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide
by: Adam N. Yadon, et al.
Published: (2017-09-01)